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Molecular biology has transformed the treatment of solid tumours
over the last decade. By improving through better biomarkers for
traditional standard of care (Mulligan et al, 2014), delivering the
promise of targeted therapeutics (Tan and Lynch, 2012) or opening
the avenue of immune checkpoint therapeutics (Sharma and
Allison, 2015), the landscape of oncology treatment has changed
substantially, and numerous new targeted therapies and predictive
diagnostics have been added to the known ER/Tamoxifen and
Her2/Trastuzumab examples. Genomic medicine, imperfect as it
may be (Tannock and Hickman, 2016), is providing some patients
with longer, better lives. And yet,B1 in 4 patients with cancer will
have these new therapeutics denied in the near future because of
the way national grant agencies and research-focused charities are
prioritising the administration of scientific resources. The work by
Alvi et al (2017), published in this issue of the BJC, supported by a
generous donation from a cancer patient, is an example of the
difficulty of aligning competitive funds to a neglected area of
cancer research.
Although some of the issues regarding rare cancers are shared
by many other diseases, there are specific questions in relation to
funding that are probably specific to rare cancers in adults.
Indeed, rare cancers comprise a staggering 198 varieties (a
complete list can be obtained at http://www.rarecarenet.eu/
rarecarenet/index.php/cancerlist) and are primarily grouped
according to the site of origin. (Rare Cancers Europe, 2017;
RARECARE, 2017). Some rare cancers are clear-cut independent
disease entities of low frequency (e.g., small bowel adenocarci-
noma with only B3000 cases diagnosed yearly in the US)
whereas others are unusual subtypes of mainstream cancers (e.g.,
colorectal signet ring cell carcinoma comprises B1% of all
colorectal carcinomas; Nitsche et al, 2013). The latter is
important because of the way we typically undertake research
– such unusual subtypes are subsumed in large cohorts of
common cancers, with no statistical power to discern their
potential genetic uniqueness and very often they simply remain
undetected, hidden amongst the common subtypes. Although
there is no agreement on a precise definition, rare cancers are
defined as those with an incidence rate of o6 per 100 000
persons per year, whereas in the US it is o15 per 100 000
(Greenlee et al, 2010; Cancer Research UK, 2016; RARECARE,
2017). Collectively, rare cancers represent B22% of all cancer
cases diagnosed in the EU and 27% of these in the USA (National
Cancer Institute Epidemiology and Genetics Research, 2017;
Rare Cancers Europe, 2017). The development of clinical trials in
rare cancers in both early and advanced disease settings has been
a major challenge, but the International Rare Cancers Initiative
has recently catalysed clinical trials across the UK, Europe, N.
America, Japan and Australasia in a variety of rare tumours
(Bogaerts et al, 2015 and see http://www.irci.info/).
Grant funding agencies and grant reviewers (most of whom may
not have had any experience in rare cancer research) face a major
problem in judging the quality of rare cancer research proposals.
Indeed, it is expected that such applications should contain all the
components that make a successful application in the common
cancer paradigm: adequate sample calculations for biomarker
discovery and validation, preliminary in vitro evidence of the
research question, cell lines and animal models to test the research
hypothesis, adequately designed and powered clinical trials and so
on. While some of these shortcomings can be tackled with
international consortia, others are very difficult if not possible
to address in the space of rare cancer research. As a result,
when looking at the main expenditure in cancer research by leading
research funding agencies, the amount of funding is generally related
to the single most prevalent forms, and does not include significant
funding for rare cancer research (https://www.everydayhealth.com/
cancer/cancer-research-where-funding-goes.aspx).
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Figure 1 depicts the 2 main models of research design when
interrogating cancer samples. On the right the ‘classic’ model is
shown, where the in vitro analysis of cell lines and mouse models
generates interesting hypotheses on disease mechanisms, disease
characterisation and novel targets. This is then confirmed with
analysis of clinical samples, either directly or via xenograft models,
and the confirmation of the clinical relevance of those findings
informs a possible clinical trial. The figure on the left provides a
schematic of the ‘alternative’ model, where direct interrogation of
the clinical materials generates the hypotheses that are then
confirmed in vitro, ahead of clinical trial design.
In either model, we have highlighted in blue the portions that
become significantly challenged when undertaking research in rare
cancer.
Despite the relative inability of cell culture models to reflect
‘clinical genomics’ (Gillet et al, 2013), or the lack of predictability
of clinical outcomes associated with the use of mouse models
(Vandamme 2014), both seem to appear as conditio sine qua non to
fund a research programme in any cancer type. Similarly, patient
derived xenografts seem to be essential for the monitoring of
cancer dynamics and complexity (Aparicio et al, 2015). However,
we know that, in rare cancers, generating these resources in
sufficient numbers or variety to make them meaningful will be an
extremely difficult, if not impossible, task. Indeed, although the
utility of these models needs to be recognised, the generation of
comprehensive ‘omics’ from well-curated clinical sample collec-
tions is a reality today and may make some of the uses of these
models redundant, particularly when the main goal of the
programme is to find actionability/druggability or to describe
dynamic determinants of therapeutics such as the cancer immune
contexture.
The characterisation of large cohorts of clinical samples to
power biomarker discovery studies in rare cancers is another
difficult task, which can be in part mitigated by large, multi-
national consortia. The problem here is that samples coming from
multiple centres, from a disease that often does not have a
nationally or internationally agreed standard of care, typically leads
to samples with diverse therapeutic interventions and pathology
curation, thus lacking the relative homogeneity of large cohorts of
common cancers. This, together with the lack of existing clinical
trials in rare cancers that could be informed by the results of
genetic studies, makes the overall landscape of research pro-
gramme argumentation difficult and frustrating.
In theory, the scientific community should not water down the
definition of good research because of aspects that are operational
rather than conceptual. And, yet, there is a strong need in the area
of rare cancers to ‘start testing’, start collecting meaningful
genomics information from whatever cohorts we may have, as
imperfect as they may be, to inform better science in the future and
start understanding alternative therapeutic interventions. Our
current era has seen the acceptance of adaptive trial designs
(Kaplan et al, 2013 and see http://www.focus4trial.org/), drug
approvals based solely on early phase trial results (Kwak et al,
2010), and the ability to obtain whole genomic/transcriptomic/
epigenetic information on small cancer cohorts that inform the
overall nature of cancer to a point never achieved before with a
candidate-based approach (Alvi et al, 2015). At the same time, we
should not judge scientific proposals and scientific merit in rare
cancer studies in the same way as we do for mainstream
malignancies, as this may not only be scientifically flawed, but
may also represent a strategic mistake that will deny therapeutic
advancement to almost a quarter of all cancer patients.
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